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SHORT REPORT
Concentration of fecal calprotectin in 11,255 children aged 0–18 years
Kaija-Leena Kolhoa and Henrik Alfthanb
aChildrens Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; bHelsinki University Hospital Laboratory
(HUSLAB), Helsinki University Hospital, Helsinki, Finland
ABSTRACT
Objectives: Fecal calprotectin is a valued surrogate marker for intestinal inflammation. It has been
argued that calprotectin levels are higher in early age than in later life hampering the use of calpro-
tectin in young children.
Subjects and methods: To study age-related variation, we used data from our laboratory information
system on consecutive, unselected fecal calprotectin measurements from 2014 to 2017 in all children
aged 0 to 18 years. From each individual, the first measurement was included and repeated measure-
ments were excluded. Fecal calprotectin was quantitated in the major clinical laboratory in southern
Finland, HUSLAB with an ELISA kit from Calpro AS (Calpro/Calprolab, Oslo, Norway). Currently, the
assay is performed on two automatic pipetting analysers (Dynex DS2, Chantilly, USA) according to the
instructions of the manufacturer.
Results: There were altogether 11,255 fecal calprotectin results from as many children. The median
level of fecal calprotectin was 51mg/kg in infants < 1 year of age (95th percentile 648mg/kg; n¼ 239).
This was 3–4-fold higher when compared to yearly age groups from 1 to 10 years (total number of
children included 5,691). Across yearly age groups from 11 to 18, the median values varied from 11 to
19mg/kg (total number of included children 5,325). The proportion of samples above the routine cut-
off for an elevated concentration >100mg/kg increased with increasing age.
Conclusions: Fecal calprotectin values in children beyond the first year of life are in general low and
comparable in children and adolescents.
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Fecal calprotectin measurement is mostly used to screen for
the possibility of inflammatory bowel disease, IBD. There is
no general consensus of the most accurate cut-off for a
raised values and cut-offs of > 50mg/kg,  100mg/kg, 
250mg/kg are most frequently used [1,2]. It is important to
keep in mind that the performance of the different calpro-
tectin ELISA assays varies regarding specificity and absolute
values [3]. There is also some individual variation on a daily
basis but this rarely hampers the diagnostic utility of the
measurement [4]. Bowel preparation for endoscopy may
affect the levels even for several days after the procedure
and therefore it is advised to take a sample if needed either
before bowel cleansing has started or not earlier than one
week after endoscopy [5].
Recently, normal values for fecal calprotectin were
described in a longitudinal cohort of infants for neonatal,
6months, 12months and 24months old infants using an
in-house turbidimetric immunoassay [6]. Fecal calprotectin val-
ues were high during the first year of life and declined there-
after. The authors suggested an upper reference limit of
57mg/kg for an increased concentration at 2 years of age. The
study cohort, however, included only 84 infants whose health
status was followed up by parental questionnaires. Another
recent report concluded that as fecal calprotectin vary accord-
ing to age, there should be different cut-offs for young age
groups and suggestions of 910mg/kg for 0–12months,
286mg/kg for >1 to 4 years and 54.4mg/kg <4 to 12years
were made. This was based on a study cohort of 174 included
children. Samples were measured with EliA 2 Calprotectin
Assay (Phadia, Sweden) [7]. Although fecal calprotectin values
seem to decrease along increasing age, there is no consensus
on whether different cut-offs should be used for children or
not. However, most authors promote separate consideration
for children younger than four years of age compared to older
children [8,9]. In Finland, fecal calprotectin measurement was
adopted early and it has been in clinical use for more than
15 years. Our laboratory has been responsible for the majority
of the analyses. This prompted us to look for the distribution
of fecal calprotectin values in a large cohort of children of
more than 10,000 assessments during a four-year period.
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Fecal calprotectin has been quantitated in the major clinical
laboratory in southern Finland, HUSLAB, with an ELISA kit
from Calpro AS (Calpro/Calprolab, Oslo, Norway) since 2008.
Currently, the assay is performed on two automatic pipetting
analysers (Dynex DS2, Chantilly, USA) according to the
instructions of the manufacturer. In brief, feces was manually
weighed (100mg) and extracted with a 50-fold excess of
extraction buffer. After centrifugation of the extract, samples
and reagents were loaded on the analyser and the assay per-
formed according to the instructions.
Study cohort
We used data from our laboratory information system (LIS) on
consecutive, unselected fecal calprotectin measurements during
four subsequent years from 2014 to 2017 in all children aged 0
to 18years. In case of follow-up samples from the same patient,
only the first sample taken during this time period was
included in the study. However, as the data are based on the
laboratory files (including encrypted patient number, date, age,
sex, requestor and the result from fecal calprotectin assay), we
had no access to the diagnoses or symptoms of the children,
whose samples were sent to the laboratory.
Our routine cut-off for an elevated value is  100mg/kg
[10]. Thus, we also assessed the proportion of elevated val-
ues at each age group according to this cut-off.
Ethics
This was a register-based study and, according to Finnish
legislation, ethical approval or informed consents were not
needed as the patients were not contacted.
Statistical analysis
Data are presented as median and interquartile range (IQR)
unless otherwise stated. If the fecal calprotectin value was
<5mg/kg, we gave a value 5 for these samples for statistical
analyses. The samples were diluted to reach exact numerical
results. Thus, there was no upper cut-off value. We used
Fisher’s exact test to determine differences in binary varia-
bles. Non-parametric Mann-Whitney test was used to com-
pare continuous variables between the groups as
appropriate. The software used for the analysis was Graph
Pad Prism version 8.0 (GraphPad Software, San Diego, CA).
The level of significance was set at a p value of < .05.
Results
Fecal calprotectin values according to age
In total, there were 11,255 samples from equally many children
aged 0 to 18years (females/males n¼ 5520/5735) analyzed for
fecal calprotectin. The results according to age groups are
shown in Table 1. During the latter two-year period the total
number of fecal calprotectin measurements had increased by
1.5% but there was no major change in the values or their dis-
tribution as such when statistically tested (data not shown).
About 80% of the samples were obtained from the county of
Uusimaa, including the capital area.
The age group younger than one year of age differed from
the other age groups in that the median concentration of fecal
calprotectin in this group was 3–4-fold higher than in the other
groups (Table 1 and Figure 1 and Supplemental Figure). In
infants less than 6months of age, the median calprotectin was
129 (IQR 51–268, n¼ 98), and in infants aged 6 to <12months
29mg/kg (IQR 13–75, n¼ 141), respectively. The difference
between these age groups was statistically significant (p< .0001).
Fecal calprotectin values exceeding the routine cut-off
The proportion of values exceeding 100mg/kg, the cut-off of
our clinical laboratory, changed according to age (Figure 2).
In the age interval 1–10 yrs the proportion was fairly stable









<1 239 51 17–157 648
1-<2 530 20 8–40 122
2-<3 514 18 8–34 109
3-<4 520 15 7–31 91
4-<5 554 16 6–34 100
5-<6 610 14 6–27 102
6-<7 602 14 6–32 110
7-<8 615 14 6–26 104
8-<9 546 14 5–34 138
9-<10 523 11 5–26 117
10-<11 677 12 5–27 147
11-<12 636 12 5–30 152
12-<13 551 11 5–28 312
13-<14 611 13 5–37 219
14-<15 702 12 5–34 328
15-<16 694 13 5–36 236
16-<17 615 16 6–48 469
17-<18 712 19 7–78 950
18-<19 804 25 8–117 1022
Figure 1. Fecal calprotectin values in children from 0 to 18 years of age in a
cohort of 11,255 samples obtained 2014–2017. Median values with 95% confi-
dence interval (CI).
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at about 5% but started to increase thereafter being about
26% in those aged 18 yrs. Upper 95% values increased
accordingly (Table 1), most likely reflecting the number of
patients with IBD.
Fecal calprotectin values according to sex
The results were comparable between boys and girls when
the whole study population was compared (Supplemental
Table 1). However, in the age groups of 17 and 18 years,
boys had significantly higher calprotectin values (medians
25mg/kg (n¼ 298) and 15mg/kg (girls n¼ 414) p< .0024
and 47mg/kg (n¼ 312) and 19mg/kg (girls n¼ 492)
p< .0001, respectively).
Discussion
Fecal calprotectin is widely used as a surrogate marker for
intestinal inflammation in adults and as well in children. The
main indication for its measurement is to screen for the possi-
bility of IBD or to follow up disease activity in diagnosed
patients with IBD [2,11–13]. Fecal calprotectin is non-specific
and raised values may be found e.g. in juvenile polyps [14],
bacterial and viral gastroenteritis [15], NSAID enteropathy or
carcinoma [1]. There is no clear consensus for a definite cut-
off for a raised value. Most manufacturers of immunoassays
suggest a cut-off of > 50mg/kg. In our clinical routine we use
a cut-off of  100mg/kg [10]. However, there are published
reports suggesting that in young children fecal calprotectin
values are higher than in adolescents and adults, and different
cut-offs should be used for various age groups [7,9,16,17].
Here we showed in a cohort of 11,255 pediatric samples that
beyond the first year of life, the median values of fecal calpro-
tectin were comparable across different age groups.
Our clinical laboratory has performed analyses of fecal cal-
protectin since 2008. From the start until now, the assay has
remained the same. For this there are two main reasons.
Firstly, the clinical performance of the assay is reliable with
high throughput. This is important as currently the total
annual number of fecal calprotectin analyses is 29,500 with
an average yearly increase of about 8%. Secondly, the per-
formance of the assay is stable with no major fluctuation in
the results. This is especially important when fecal calprotec-
tin values are followed up and used in clinical deci-
sion-making.
In previous studies, it has been suggested that fecal cal-
protectin is not as reliable surrogate marker in children
younger than four years of age compared to adults. The rea-
son for this conclusion was that values are higher in young
children [9,16,17]. Recently, it was stated that due to variable
levels, fecal calprotectin should be used with caution in chil-
dren younger than 10 years of age [8]. Our results do not
support these conclusions as we found no significant differ-
ence in median calprotectin values in pediatric samples
beyond one year of age. Our cohort is the largest in sample
size reported so far and all the previous studies included
considerably lower number of samples.
On contrary, fecal calprotectin was higher during the first
year of life as we observed here and as has been reported
[6,7,17–19]. It has been suggested that the increased perme-
ability of the gut might increase the influx of inflammatory
cells in the gut in babies and thus, have an impact on the
higher fecal calprotectin values. Sex has no effect on fecal
calprotectin values [16]. In our large study cohort, fecal cal-
protectin values were in general comparable between boys
and girls.
We compared the fecal calprotectin test results in pediat-
ric samples in two sequential two-year periods and found no
major differences in the absolute values but there was an
increase of 1.5% in the total number of analyses. In adoles-
cents beyond 15 years of age, the proportion of fecal calpro-
tectin values above the clinical cut-off started to increase.
Also, among the 17 and 18 -year-olds, boys showed higher
calprotectin values. These findings may reflect the overall
increase in the incidence of pediatric IBD among adolescents
in our country as in IBD fecal calprotectin values are much
higher than in healthy children or children with other dis-
eases [20,21]. However, as this was a register-based study,
we did not have access to the clinical indications or diagno-
ses of the patients whose samples were included.
In conclusion, in a large group of pediatric samples, we
observed no major differences in the median values of fecal
calprotectin in yearly age groups beyond one year of age.
During the first year of life, fecal calprotectin values were
clearly higher than in later life. The reasons for this are
yet undefined.
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Figure 2. Proportion of fecal calprotectin values >100mg/kg (routine cut-off
for a raised value).
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